BioCurex, Inc.(fka BOCX)

[dakota]

BioCurex Signs Consent to Transfer Abbott's RECAF Licensing Agreement to General Electric
RICHMOND, British Columbia, July 2, 2007 (PRIME NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) announced today that, upon request from Abbott Labs, the Company has signed a document transferring Abbott's RECAF licensing agreement to General Electric (GE).


On January 18, 2007 Abbott Laboratories announced that it intended to transfer its core diagnostics and point of care business to GE on or around April 2, 2007.

For full Abbott Laboratories press release click here: http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0420.htm

As of the transfer date, Abbott Laboratories intends to assign to GE the BioCurex semi-exclusive license agreement. At that time, GE will accept and assume all rights and obligations under the license agreement.

In the last two years Abbott Diagnostics and BioCurex have collaborated intensively and as a result the RECAF serum test is closer to commercialization. During this R and D period it was demonstrated that RECAF can detect 90% of stage I and II breast cancers and 75% of stages I and II of prostate cancers. The coordinated work between the companies has resulted in significant advances towards the ability of automated lab machines to detect cancer using the RECAF technology in combination with proprietary technology. It is expected that this work will continue on schedule.

"We are extremely pleased with this licensing agreement transfer to General Electric. The GE Healthcare Division is dedicated to providing healthcare providers with state-of-the-art products designed to better diagnose and treat cancer," stated Ricardo Moro, President and CEO. "We anticipate that our new relationship with GE Healthcare will accelerate the progress that we've made with Abbott Diagnostics toward the commercialization of RECAF."

Click this link to read more about GE's Oncology division: http://www.gehealthcare.com/usen/oncology/index.html